

In the Claims

Claims 1-32 (Cancelled)

Claim 33 (Currently amended): An immunogenic composition comprising nanospheres, wherein said nanospheres comprise plasmid DNA coacervated with chitosan, ~~and~~ wherein said plasmid DNA encode respiratory syncytial virus (RSV) antigens M2, F, G, M, SH, NS1, NS2, N, and P, and wherein said plasmid DNA are expressed *in vivo*, thereby producing each of said RSV antigens.

Claims 34-36 (Cancelled)

Claim 37 (Withdrawn): A method for raising an immune response in a host against RSV, comprising administering to the host an immunoeffective amount of the immunogenic composition of claim 33.

Claim 38 (Withdrawn): The method of claim 37, wherein said administering is oral or intranasal.

Claim 39 (Withdrawn): The method of claim 37, wherein said administering does not induce airway hyperreactivity.

Claim 40 (Withdrawn): The method of claim 37, wherein the immunoeffective amount is administered in a single dose.

Claim 41 (Withdrawn): The method of claim 37, wherein the immunoeffective amount is about 1 mg/kg host weight.

Claims 42-44 (Cancelled)

Claim 45 (Withdrawn): A method of making the immunogenic composition of claim 33, comprising coacervating the plasmid DNA with chitosan to form the nanospheres.

Claims 46-48 (Cancelled)

Claim 49 (Withdrawn): The method of claim 45, further comprising cloning cDNA encoding the RSV antigens in plasmids to form the plasmid DNA.

Claim 50 (Currently amended): An immunogenic composition comprising nanospheres, wherein said nanospheres comprise plasmid DNA coacervated with chitosan, wherein said plasmid DNA encode respiratory syncytial virus (RSV) antigens M2, F, G, M, SH, NS1, NS2, N, and P, and wherein said immunogenic composition is an inhalant, and wherein said plasmid DNA are expressed *in vivo*, thereby producing each of said RSV antigens.

Claims 51-53 (Cancelled)